(Corrects eighth paragraph to show company is now based in
California; second paragraph to make clear the company left
Applera earlier this year)
WASHINGTON Aug 4 A blood test that detects
nine compounds in blood may offer a safe way to diagnose early
cases of lung cancer, Celera Corporation CRA.O reported on
Such a test would allow quick treatment of lung cancer,
which is usually not detected before it has spread, Celera,
which became independent of Applera Corp. earlier this year,
said in a statement.
"This is one of the most promising assays I've seen as a
predictor of non-small cell lung cancer," Dr. Harvey Pass of
the New York University Langone Medical Center, who helped test
the diagnostic, said in a statement.
The researchers tested people who had been diagnosed with
stage 1 lung cancer, which can often be cured, and found it
detected the cancer with more than 90 percent accuracy.
The test uses a mass spectrometer to detect the nine
compounds in the blood. They are also working on a simpler test
that looks for six compounds, the researchers told the
International Association for the Study of Lung Cancer in San
Overall, they tested 103 patients with non-small-cell-lung
cancer and smokers without the disease.
Lung cancer is the leading cause of cancer death globally,
killing 1.2 million people a year. Most cases are diagnosed
after the cancer has spread from the lung, when it cannot be
California-based Celera, founded by gene pioneer Craig
Venter as a genetic discovery company, has re-branded itself as
a maker of diagnostic tests.